These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1143006)

  • 21. Metabolism of a tryptophan load in the hypothalamus and other brain regions.
    Curzon G; Marsden CA
    J Neurochem; 1975 Sep; 25(3):251-6. PubMed ID: 125780
    [No Abstract]   [Full Text] [Related]  

  • 22. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
    Lindén IB; Nissinen E; Etemadzadeh E; Kaakkola S; Männistö P; Pohto P
    J Pharmacol Exp Ther; 1988 Oct; 247(1):289-93. PubMed ID: 3171977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
    Rodgers KJ; Hume PM; Morris JG; Dean RT
    J Neurochem; 2006 Aug; 98(4):1061-7. PubMed ID: 16771833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphine effects on the levels and turnover of catecholamines in rat brain.
    Johnson JC; Ratner M; Gold CJ; Clouet DH
    Res Commun Chem Pathol Pharmacol; 1974 Sep; 9(1):41-53. PubMed ID: 4438827
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics of L-dopa in patients with Parkinson's disease.
    Mena MA; Muradas V; Bazan E; Reiriz J; de Yebenes JG
    Adv Neurol; 1987; 45():481-6. PubMed ID: 2950730
    [No Abstract]   [Full Text] [Related]  

  • 26. Where is L-DOPA decarboxylated in the striatum after 6-hydroxydopamine nigrotomy?
    Duvoisin RC; Mytilineou C
    Brain Res; 1978 Aug; 152(2):369-73. PubMed ID: 567088
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of L-DOPA on glucose oxidation and incorporation into glycogen in discrete brain regions of the rat.
    Barash V; Globus M; Melamed E; Weidenfeld J
    Brain Res; 1985 Jun; 335(2):347-9. PubMed ID: 4005564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3-O-Methyldopa in Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Adv Neurol; 1974; 5():309-15. PubMed ID: 4440579
    [No Abstract]   [Full Text] [Related]  

  • 29. Possible circadian and seasonal rhythmicity in an in vitro model: monoamine uptake in rat brain slices.
    Wirz-Justice A
    Experientia; 1974 Nov; 30(11):1240-1. PubMed ID: 4474089
    [No Abstract]   [Full Text] [Related]  

  • 30. β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
    Huang L; Deng M; He Y; Lu S; Ma R; Fang Y
    Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):634-43. PubMed ID: 26991136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of 3-OM-dopa on monoamine metabolism in rat brain.
    Gervas JJ; Muradás V; Bazán E; Aguado EG; de Yébenes JG
    Neurology; 1983 Mar; 33(3):278-82. PubMed ID: 6681870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of increased rat brain tryptophan on 5-hydroxytryptamine and 5-hydroxyindolyl acetic acid in the hypothalamus and other brain regions.
    Knott PJ; Curzon G
    J Neurochem; 1974 Jun; 22(6):1065-71. PubMed ID: 4851651
    [No Abstract]   [Full Text] [Related]  

  • 33. Catechol-O-methyltransferase activity: a determinant of levodopa response.
    Reilly DK; Rivera-Calimlim L; Van Dyke D
    Clin Pharmacol Ther; 1980 Aug; 28(2):278-86. PubMed ID: 7398195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
    Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
    Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the 5-HT-binding sites in the cerebral cortex, striatum and hypothalamus of rats during ageing and under the effect of dopaminergic agents.
    Petkov VD; Petkov VV; Popova J; Konstantinova E
    Acta Physiol Pharmacol Bulg; 1987; 13(1):11-9. PubMed ID: 3039800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of L-dopa in human serum.
    Dizdar N; Arstrand K; Kågedal B
    Biotechniques; 2002 Nov; 33(5):1000, 1002. PubMed ID: 12449374
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
    Cedarbaum JM; Kutt H; McDowell FH
    Neurology; 1988 Apr; 38(4):533-6. PubMed ID: 3352906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative evaluation of the blood-brain barrier capacity to form dopamine from circulating L-DOPA.
    Hardebo JE; Edvinsson L; Owman C; Rosengren E
    Acta Physiol Scand; 1977 Mar; 99(3):377-84. PubMed ID: 848309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cholecystokinin antiserum on the brain monoamine content in rats.
    Fekete M; Kádár T; Telegdy G
    Acta Physiol Acad Sci Hung; 1981; 57(2):177-83. PubMed ID: 7315376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interaction of L-DOPA and pyridoxine (a review of the literature)].
    Uspenskiĭ AE
    Farmakol Toksikol; 1977; 40(6):722-33. PubMed ID: 340258
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.